Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous macrophage therapy - ProNeuron

Drug Profile

Autologous macrophage therapy - ProNeuron

Alternative Names: Autologous incubated macrophage therapy; ProCord

Latest Information Update: 13 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proneuron Biotechnologies
  • Class Cell therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity No

Highest Development Phases

  • No development reported Spinal cord injuries

Most Recent Events

  • 13 Aug 2015 No recent reports on development identified - Phase-I for Spinal cord injuries in Belgium (unspecified route)
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Spinal cord injuries in Israel, USA (unspecified route)
  • 19 Sep 2005 Data from a media release have been added to the adverse events and Neurological Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top